Tetra Bio Pharma Inc
TSX:TBP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Tetra Bio Pharma Inc
Cash from Investing Activities
Tetra Bio Pharma Inc
Cash from Investing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Tetra Bio Pharma Inc
TSX:TBP
|
Cash from Investing Activities
-CA$683.8k
|
CAGR 3-Years
42%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Cash from Investing Activities
-$595m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
28%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Cash from Investing Activities
CA$20.3m
|
CAGR 3-Years
-68%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
Cash from Investing Activities
-$76.6m
|
CAGR 3-Years
-246%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-52%
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Cash from Investing Activities
-$186.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Cash from Investing Activities
-CA$75.2m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-1%
|
|
Tetra Bio Pharma Inc
Glance View
Tetra Bio-Pharma, Inc. engages in the discovery and development of cannabinoid-based drugs and treatments. The company is headquartered in Orleans, Ontario and currently employs 33 full-time employees. The company went IPO on 2008-04-15. The firm is engaged in the development of bio pharmaceuticals and natural health products containing cannabis and other medicinal plant-based elements. The firm is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. The firm's objective is to bring prescription drugs and treatments to relieve symptoms associated with advanced cancer pain, chronic pain, Acute Respiratory Distress Syndrom (ARDS), sepsis and ophthalmic disease. Its products include QIXLEEF, CAUMZ, REDUVO Capsules, REDUVO Adversa, ARDS-003 and PPP-002. Its QIXLEEF is a botanical inhaled drug with a fixed ratio of tetrahydrocannabinol (THC) and cannabidiol (CBD).
See Also
What is Tetra Bio Pharma Inc's Cash from Investing Activities?
Cash from Investing Activities
-683.8k
CAD
Based on the financial report for Aug 31, 2022, Tetra Bio Pharma Inc's Cash from Investing Activities amounts to -683.8k CAD.
What is Tetra Bio Pharma Inc's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 5Y
-22%
Over the last year, the Cash from Investing Activities growth was 79%. The average annual Cash from Investing Activities growth rates for Tetra Bio Pharma Inc have been 42% over the past three years , -22% over the past five years .
